Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Harit Desai

Interventional Cardiology Pennington, NJ Doctor of Osteopathy

NPI 1548472905 CMS profile 297241

2 Capital Way Ste 385, Ste 385, Pennington, NJ 08534

Open in the dashboard

General payments

$7,646

163 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Harit Desai of Pennington, NJ is reported in the CMS Open Payments database as having received $7,646 across 163 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 51st percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,872 46
2024 General $1,783 23
2023 General $666 15
2022 General $1,121 37
2021 General $532 21
2020 General $114 8
2019 General $559 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Harit Desai
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Harit Desai were reported at $2,872. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Harit Desai Interventional Cardiology median Middle half National median
2019 $559 $1,097 $329–$3,048 $163
2020 $114 $473 $161–$1,480 $114
2021 $532 $677 $233–$1,827 $132
2022 $1,121 $978 $333–$2,724 $149
2023 $666 $1,136 $382–$2,986 $160
2024 $1,783 $1,181 $395–$3,326 $164
2025 $2,872 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $2,967 36 payments
  2. Edwards Lifesciences Corporation $1,771 27 payments
  3. Boston Scientific Corporation $585 6 payments
  4. Abbott Laboratories $534 16 payments
  5. Shockwave Medical, Inc $314 9 payments
  6. Abiomed $240 11 payments
  7. Medtronic Vascular, Inc. $207 6 payments
  8. Inari Medical, Inc. $144 1 payment
  9. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $119 6 payments
  10. Janssen Pharmaceuticals, Inc $119 8 payments
  11. Other $647 37 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,387 152 payments
  2. Travel and Lodging $1,259 11 payments
Products named General payments · program years 2019–2025
  1. COREVALVE EVOLUT R $2,575 28 payments
  2. SAPIEN 3 Ultra RESILIA $631 9 payments
  3. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $314 9 payments
  4. Impella $218 10 payments
  5. WATCHMAN $211 2 payments
  6. PASCAL $209 1 payment
  7. SYMPLICITY G3 $173 1 payment
  8. MITRACLIP $165 1 payment
  9. Resolute $157 3 payments
  10. CT THROMBECTOMY SYSTEM KIT $144 1 payment
  11. Other $1,884 84 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

1,770

Median for Internal Medicine: 777

Drug cost

$357,192

Median for Internal Medicine: $73,373

Branded share of claims

28.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 84 $103,086
Eliquis Apixaban Brand 80 $101,259
Repatha Sureclick Evolocumab Brand 34 $42,892
Brilinta Ticagrelor Brand 38 $40,153
Praluent Pen Alirocumab Brand 22 $25,457
Entresto Sacubitril/Valsartan Brand 11 $20,220
Rosuvastatin Calcium Generic 187 $3,412
Metoprolol Succinate Generic 237 $3,169
Atorvastatin Calcium Generic 196 $2,616
Valsartan Generic 78 $2,612

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 69 billing codes

Paid by Medicare

$140,673

Medicare's payments for the services billed

Medicare patients

558

Average age 76

Services billed

1,539

272 women, 286 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 70%
Arthritis 52%
Diabetes 48%
Heart failure 41%
Chronic kidney disease 39%
Atrial fibrillation 38%
COPD 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
  • Amgen Inc. $17
$17 34 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

163 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record